PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
News|Articles|October 13, 2023
Validated processes in granulation - How to produce the perfect particle
Author(s)Diosna
Do you face challenges when it comes to the particle quality in your granulation process? In order to produce granules with the desired properties, scale-up is crucial, in addition to looking at the process parameters. After all, the path of a drug from the laboratory to production holds many a surprise. Especially in the case of particles for inhalers, the mixing process plays a decisive role. Learn what you need to consider to produce the perfect particle. This whitepaper reveals expert know-how on the mixing details, the key figures to consider and the positive effects using the practical example of inhalants.
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
What the Olanzapine Depot Approval Means for CMC Teams
3
Complying with International Pharmacopoeias
4
Q&A: Patient-Centric Drug Development Should Start at Product Definition
5